• Explore /
  • Poster
  • / Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Niven Mehra

Niven Mehra

Radboud University Medical Center, Nijmegen, Netherlands

Niven Mehra , Debbie Robbrecht , Jens Voortman , Paul WHI Parren , Sonia Macia , Jorden Veeneman , Sanjana Umarale , Benjamin Winograd , Hans J. van der Vliet , David R Wise

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05369000

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 153)

DOI

10.1200/JCO.2023.41.6_suppl.153

Abstract #

153

Poster Bd #

E13

Abstract Disclosures

Similar Posters

First Author: Christopher Hackenbruch

First Author: William Kevin Kelly

Poster

2022 ASCO Genitourinary Cancers Symposium

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Susan F. Slovin

First Author: Jingsong Zhang